NDC PHARMA
ActiveSummary
NDC PHARMA has been active since 1986 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €234,089 and a net result of €188,352. Equity is shrinking by about 4% per year across the filed financial years. Its solvency ranks better than 43% of 12,578 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2025
29-12
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
30-06
Financial
Highest result from 2019 to 2025net €188,352 ▲85.6%
Operating result €200,631, net result €188,352, both a record.
10-01
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format
2024
19-01
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format
2023
31-01
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format
2022
30-06
Financial
Back to profitnet €153,347
Net result €153,347 after one loss-making year.
17-01
NBB filing
Annual accounts filed
financial year 2021 · abbreviated format
2021
30-06
Financial
Weakest financial yearnet -€25,752
Net result drops to -€25,752, the lowest in the series; recovery starts the following year.
2020
15-12
NBB filing
Annual accounts filed
financial year 2020 · abbreviated format
15-01
NBB filing
Annual accounts filed
financial year 2019 · abbreviated format
2018
17-12
NBB filing
Annual accounts filed
financial year 2018 · abbreviated format
2017
25-07
NBB filing
Annual accounts filed
financial year 2016 · abbreviated format
2016
12-07
NBB filing
Annual accounts filed
financial year 2015 · abbreviated format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 39 annual accounts filed, the latest 10 are here; all 39 are under Financials.
0 of 5 deeds read
About the unread acts
We know of 5 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.